Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
The Pharma Data
JUNE 17, 2022
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients Submission builds on Sandoz’ well established biosimilar immunology portfolio in Europe.
52 
Let's personalize your content